Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label study of two-dose AS03A-adjuvanted pandemic H1N1 vaccine in adults
2009-015008-25Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Q-Pan H1N1 in influenza A virus infection (H1N1), sponsored by GSK. Primary endpoints: Humoral immune response in terms of haemagglutination inhibition antibodies, Seroconversion rate at 21 days after second dose and 2 more. Started Sep 2009; status: completed.
02
Drugs
Q-Pan H1N1
03
Conditions
influenza A virus infection (H1N1)
Beyond the preview
Go deeper on 2009-015008-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015008-25.